# Agomelatine

## Valdoxan 25mg

##### 

| TAH Drug Code      | OVALD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of major depression in adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | The recommended daily dose: 25mg orally HS. After two weeks of treatment, if there is no improvement in symptoms, the dose may be increased to 50mg once daily, taken as a single dose at bedtime. The maximum recommended dose should not be exceeded.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | 1. Patients with a history of previous hypersensitivity to the active ingredient or any of the excipients 2.Patients with hepatic impairment (i.e. cirrhosis or active liver disease) 3. Taking potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Nervous system: Headache (14.1%), Dizziness (5.5%), Somnolence (2.9%), Migraine(1.2%), Tremor (1%), paraesthesia (0.9%) Gastrointestinal: Nausea (7.7%), Dry mouth (3.5%), Diarrhea (3.1%), Abdominal pain upper (2.4%), Constipation (1.8%), Dyspepsia (1.3%) Infections and infestations: Influenza (2.3%), Nasopharyngitis (2.1%) Psychiatric: Insomnia (2.4%), Anxiety (2%), Depression (1.3%) General: Fatigue (2.6%) Skin and subcutaneous tissue: Hyperhidrosis (1.3%), eczema (0.2%), erythematous rash (0.1%) Musculoskeletal and connective tissue: Back pain (1.5%) Ear and labyrinth: Vertigo (1.1%) Eye disorders: blurred vision (0.6%). Hepato-biliary disorders: increases (>3 times the upper limit of the normal range) in ALT and/or AST (1.1%), hepatitis (0.03%) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

